Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Mitoxantrone, vinorelbine and prednisone (MVD) in the treatment of metastatic hormonoresistant prostate cancer — a phase II trial

Prostate Cancer and Prostatic Diseases volume 7, pages 45–49 (2004)Cite this article

Abstract

A total of 28 patients were treated with mitoxantrone, vinorelbine and prednisone every 3 weeks. In all, 11 patients (46%) had a significant prostate-specific antigen decline for a median duration of 11.4 months. Eight patients (33%) achieved a partial response on pain, while seven (29%) obtained a stabilisation of the symptom. Median duration of the response was 9.5 months. A confirmed partial response was obtained in three out of seven patients who had bidimensionally measurable disease. Toxicity was manageable. Our study provides further support to the concept of combined antimicrotubule therapy for metastatic harmonoresistant prostate cancer, promoting the exploration of new regimens containing antimicrotubule agents in addition to mitoxantrone–prednisone.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Parker SL, Tong T, Bolden S, Wingo PA . Cancer statistics. CA Cancer J Clin 1997; 47: 5–27.

    Article  CAS  Google Scholar 

  2. Goktas S, Crawford ED . Optimal hormonal therapy for advanced prostatic carcinoma. Semin Oncol 1999; 26: 162–173.

    CAS  PubMed  Google Scholar 

  3. Oh WK . Chemotherapy for patients with advanced prostate carcinoma. Cancer 2000; 88: 3015–3021.

    Article  CAS  Google Scholar 

  4. Culine S, Droz J-P . Chemotherapy in advanced androgen-independent prostate cancer 1990–1999: A decade of progress? Ann Oncol 2000; 11: 1523–1530.

    Article  CAS  Google Scholar 

  5. Eisenberger MA . Chemotherapy for prostate carcinoma. NCI Monogr 1988; 7: 151–163.

    Google Scholar 

  6. Yagoda A, Petrylak D . Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993; 71: 1098–1099.

    Article  CAS  Google Scholar 

  7. Dawson NA . Response criteria in prostatic carcinoma. Semin Oncol 1999; 26: 174–184.

    CAS  PubMed  Google Scholar 

  8. Bubley GJ et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen working group. J Clin Oncol 1999; 17: 3461–3467.

    Article  CAS  Google Scholar 

  9. Tannock IF et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14: 1756–1764.

    Article  CAS  Google Scholar 

  10. Kantoff PW et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 1999; 17: 2506–2513.

    Article  CAS  Google Scholar 

  11. Isaacs JT . The biology of hormone-refractory prostate cancer: why does it develop? Urol Clin North Am 1999; 26: 263–273.

    Article  CAS  Google Scholar 

  12. Depierre A et al. A phase II study of navelbine (vinorelbine) in the treatment of non-small-cell lung cancer. Am J Clin Oncol 1991; 14: 115–119.

    Article  CAS  Google Scholar 

  13. Le Chevalier T et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancers: results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12: 360–367.

    Article  CAS  Google Scholar 

  14. Marty M et al. A review of antitumour activity of vinorelbine in breast cancer. Drugs 1992; 44: 29–35.

    Article  CAS  Google Scholar 

  15. Fields-Jones S et al. Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: a phase II trial. Ann Oncol 1999; 10: 1307–1310.

    Article  CAS  Google Scholar 

  16. Morant R et al. Vinorelbine in androgen-independent metastatic prostate carcinoma — a phase II study. Eur J Cancer 2002; 38: 1626–1632.

    Article  CAS  Google Scholar 

  17. WHO Handbook for reporting results of cancer treatment. WHO Offset Publication No. 48. Geneva, Switzerland, World Health Organization, 1979.

  18. Oudard S et al. Phase II study of vinorelbine in patients with androgen-independent prostate cancer. Ann Oncol 2001; 12: 847–852.

    Article  CAS  Google Scholar 

  19. Houde RW . Methods for measuring clinical pain in humans. Acta Anaesthesiol Scand 1982; 74:(Suppl): 25–29.

    Article  CAS  Google Scholar 

  20. Kelly WK et al. Prostate specific antigen as a measure of disease outcome in metastatic hormono-refractory prostate cancer. J Clin Oncol 1993; 11: 607–615.

    Article  CAS  Google Scholar 

  21. Sweeney CJ et al. A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer. Ann Oncol 2002; 13: 435–440.

    Article  CAS  Google Scholar 

  22. Colleoni M et al. Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer. Am J Clin Oncol 1997; 20: 383–386.

    Article  CAS  Google Scholar 

  23. Smith MR et al. Vinorelbine and estramustine in androgen-independent metastatic prostate cancer. A phase II study. Cancer 2000; 89: 1824–1828.

    Article  CAS  Google Scholar 

  24. Hudes GR et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 1997; 15: 3156–3163.

    Article  CAS  Google Scholar 

  25. Smith DC et al. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol 1999; 17: 1664–1671.

    Article  CAS  Google Scholar 

  26. Savarese DM et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. J Clin Oncol 2001; 19: 2509–2516.

    Article  CAS  Google Scholar 

  27. Oudard S et al. Preliminary results of a phase II randomized trial of docetaxel, estramustine and prednisone—two schedules versus mitoxantrone and prednisone in patients with hormone refractory prostate cancer. Proc Am Soc Clin Oncol 2002; 21: 177a (abstract 706).

    Google Scholar 

  28. Sinibaldi VJ et al. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer 2002; 94: 1457–1465.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by the ISS (Istituto Superiore di Sanità) and AIRC (Associazione Italiana per la Ricerca sul Cancro) grants.

Author information

Authors and Affiliations

  1. Division of Medical Oncology A, Centro di Riferimento Oncologico, Aviano (PN), Italy

    D Bernardi, M Zanetti, C Simonelli, E Vaccher, M Spina & U Tirelli

  2. Epidemiology Unit, Centro di Riferimento Oncologico, Aviano (PN), Italy

    R Talamini

Authors
  1. D Bernardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R Talamini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Zanetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Simonelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E Vaccher
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Spina
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. U Tirelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D Bernardi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bernardi, D., Talamini, R., Zanetti, M. et al. Mitoxantrone, vinorelbine and prednisone (MVD) in the treatment of metastatic hormonoresistant prostate cancer — a phase II trial. Prostate Cancer Prostatic Dis 7, 45–49 (2004). https://doi.org/10.1038/sj.pcan.4500685

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500685

Keywords

Search

Advanced search

Quick links